Eline Picavet

511 total citations
20 papers, 299 citations indexed

About

Eline Picavet is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Management of Technology and Innovation. According to data from OpenAlex, Eline Picavet has authored 20 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Economics and Econometrics, 9 papers in Pediatrics, Perinatology and Child Health and 3 papers in Management of Technology and Innovation. Recurrent topics in Eline Picavet's work include Health Systems, Economic Evaluations, Quality of Life (17 papers), Pharmaceutical Economics and Policy (14 papers) and Pharmaceutical studies and practices (9 papers). Eline Picavet is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (17 papers), Pharmaceutical Economics and Policy (14 papers) and Pharmaceutical studies and practices (9 papers). Eline Picavet collaborates with scholars based in Belgium, Netherlands and Portugal. Eline Picavet's co-authors include David Cassiman, Steven Simoens, Marc Dooms, Thomas Morel, Irina Cleemput, Lieven Annemans, Carla E. M. Hollak, Johan Maertens, Bruno Sepodes and Segundo Mariz and has published in prestigious journals such as Nature Reviews Drug Discovery, Drugs and Value in Health.

In The Last Decade

Eline Picavet

19 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eline Picavet Belgium 11 217 90 44 40 27 20 299
Josep Torrent-Farnell Spain 6 164 0.8× 60 0.7× 37 0.8× 27 0.7× 28 1.0× 10 256
Marlene E. Haffner United States 9 167 0.8× 80 0.9× 85 1.9× 36 0.9× 49 1.8× 23 323
Hanna I. Hyry United Kingdom 7 128 0.6× 43 0.5× 31 0.7× 16 0.4× 34 1.3× 8 230
Francis Arickx Belgium 6 160 0.7× 38 0.4× 22 0.5× 14 0.3× 15 0.6× 11 209
Enrico Costa Italy 8 91 0.4× 63 0.7× 39 0.9× 13 0.3× 39 1.4× 26 284
Meredith Weaver United States 7 59 0.3× 16 0.2× 70 1.6× 104 2.6× 66 2.4× 15 226
Liese Barbier Belgium 9 224 1.0× 119 1.3× 13 0.3× 5 0.1× 13 0.5× 36 362
Nathalie Bere Netherlands 5 88 0.4× 22 0.2× 9 0.2× 3 0.1× 12 0.4× 8 158
Juan Carlos Rejón-Parrilla United Kingdom 8 102 0.5× 14 0.2× 11 0.3× 3 0.1× 11 0.4× 15 197
Courtney D. Storm United States 7 30 0.1× 52 0.6× 263 6.0× 6 0.1× 87 3.2× 9 434

Countries citing papers authored by Eline Picavet

Since Specialization
Citations

This map shows the geographic impact of Eline Picavet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eline Picavet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eline Picavet more than expected).

Fields of papers citing papers by Eline Picavet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eline Picavet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eline Picavet. The network helps show where Eline Picavet may publish in the future.

Co-authorship network of co-authors of Eline Picavet

This figure shows the co-authorship network connecting the top 25 collaborators of Eline Picavet. A scholar is included among the top collaborators of Eline Picavet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eline Picavet. Eline Picavet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Picavet, Eline, et al.. (2017). Market Access of Nintedanib for Idiopathic Pulmonary Fibrosis: A Cross-Country Review of Access Conditions. Value in Health. 20(9). A566–A566. 2 indexed citations
2.
Picavet, Eline, et al.. (2017). Systematic Review of The Cost-Effectiveness of Medicines For The Treatment of Idiopathic Pulmonary Fibrosis. Value in Health. 20(9). A555–A555. 1 indexed citations
3.
Morel, Thomas, et al.. (2016). The orphan drug pipeline in Europe. Nature Reviews Drug Discovery. 15(6). 376–376. 11 indexed citations
4.
Picavet, Eline, David Cassiman, & Steven Simoens. (2015). What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses. Journal of Clinical Pharmacy and Therapeutics. 40(3). 304–307. 13 indexed citations
5.
Picavet, Eline, Thomas Morel, David Cassiman, & Steven Simoens. (2014). Shining a light in the black box of orphan drug pricing. Orphanet Journal of Rare Diseases. 9(1). 62–62. 39 indexed citations
6.
Picavet, Eline, David Cassiman, & Steven Simoens. (2014). Reimbursement of orphan drugs in Belgium: what (else) matters?. Orphanet Journal of Rare Diseases. 9(1). 139–139. 21 indexed citations
7.
Picavet, Eline, David Cassiman, Carla E. M. Hollak, Johan Maertens, & Steven Simoens. (2013). Clinical evidence for orphan medicinal products-a cause for concern?. Orphanet Journal of Rare Diseases. 8(1). 164–164. 25 indexed citations
8.
Picavet, Eline, David Cassiman, Bert Aertgeerts, & Steven Simoens. (2013). Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool. Orphanet Journal of Rare Diseases. 8(1). 157–157. 4 indexed citations
9.
Picavet, Eline, David Cassiman, & Steven Simoens. (2013). Do ultra-orphan medicinal products warrant ultra-high prices? A review. 23–23. 6 indexed citations
10.
Picavet, Eline, David Cassiman, Wim Pinxten, & Steven Simoens. (2013). Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium. Expert Review of Pharmacoeconomics & Outcomes Research. 13(5). 571–573. 9 indexed citations
11.
Simoens, Steven, Eline Picavet, David Cassiman, & Marc Dooms. (2012). PHP15 What Price do we Pay for Repurposing Medicines for Rare Diseases?. Value in Health. 15(4). A15–A16. 4 indexed citations
12.
Picavet, Eline, David Cassiman, & Steven Simoens. (2012). Evaluating and improving orphan drug regulations in Europe: A Delphi policy study. Health Policy. 108(1). 1–9. 17 indexed citations
13.
Picavet, Eline, Lieven Annemans, Irina Cleemput, David Cassiman, & Steven Simoens. (2012). Market uptake of orphan drugs - a European analysis. Journal of Clinical Pharmacy and Therapeutics. 37(6). 664–667. 28 indexed citations
14.
Simoens, Steven, David Cassiman, Marc Dooms, & Eline Picavet. (2012). Orphan Drugs for Rare Diseases. Drugs. 72(11). 1437–1443. 45 indexed citations
15.
Picavet, Eline, Marc Dooms, David Cassiman, & Steven Simoens. (2012). Orphan Drugs for Rare Diseases: Grounds for Special Status. Drug Development Research. 73(3). 115–119. 18 indexed citations
16.
Simoens, Steven, et al.. (2012). What price do we pay for repurposing medicines for rare diseases. 15–16. 3 indexed citations
17.
Picavet, Eline, Marc Dooms, David Cassiman, & Steven Simoens. (2011). Drugs for rare diseases – influence of orphan designation status on price. Value in Health. 14(7).
18.
Picavet, Eline, Marc Dooms, David Cassiman, & Steven Simoens. (2011). PHP28 Drugs for Rare Diseases: Influence of Oprhan Designation Status on Price. Value in Health. 14(7). A338–A338. 1 indexed citations
19.
Picavet, Eline, Marc Dooms, David Cassiman, & Steven Simoens. (2011). Drugs for Rare Diseases: Influence of Orphan Designation Status on Price. Applied Health Economics and Health Policy. 9(4). 275–279. 41 indexed citations
20.
Simoens, Steven, David Cassiman, Eline Picavet, & Marc Dooms. (2011). Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. Drugs & Therapy Perspectives. 27(10). 24–26. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josep Torrent-Farnell Breakdown of academic impact, for papers by Marlene E. Haffner Breakdown of academic impact, for papers by Hanna I. Hyry Breakdown of academic impact, for papers by Francis Arickx Breakdown of academic impact, for papers by Enrico Costa Breakdown of academic impact, for papers by Meredith Weaver Breakdown of academic impact, for papers by Liese Barbier Breakdown of academic impact, for papers by Nathalie Bere Breakdown of academic impact, for papers by Juan Carlos Rejón-Parrilla Breakdown of academic impact, for papers by Courtney D. Storm
Rankless by CCL
2026